

This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Markers			
MicroRNA signatures for lung cancer	<p>miRNA signatures could help diagnose and guide treatment of non-small cell lung cancer (NSCLC). In plasma samples, a 13-miRNA signature distinguished NSCLC patients from healthy controls with 75% sensitivity and 100% specificity ($p < 0.0001$). Also in plasma samples, a 9-miRNA signature predicted risk of aggressive cancer with 80% sensitivity and 100% specificity ($p = 0.0001$). Next steps include validating the miRNA signatures in a larger cohort of patients and developing a laboratory device for analyzing miRNAs from plasma samples.</p> <p>SciBX 4(9); doi:10.1038/scibx.2011.268 Published online March 3, 2011</p>	<p>Patent application filed; licensing status undisclosed</p>	<p>Boeri, M. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Feb. 7, 2011; doi:10.1073/pnas.1100048108 Contact: Gabriella Sozzi, National Cancer Institute, Milan, Italy e-mail: gabriella.sozzi@istitutotumori.mi.it Contact: Carlo M. Croce, The Ohio State University, Columbus, Ohio e-mail: carlo.croce@osumc.edu</p>